Capital International’s NovoCure NVCR Stock Holding History

Capital International’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-82,588	Closed	-$3.43M	–	160
2023 Q2	$3.43M	Sell	82,588 -18,239	-18%	-$1.13M	0.19%	116
2023 Q1	$6.06M	Buy	100,827 +14,979	+17%	+$1.2M	0.36%	85
2022 Q4	$6.3M	Sell	85,848 -1,055	-1%	-$79.4K	0.43%	77
2022 Q3	$6.6M	Sell	86,903 -5,329	-6%	-$416K	0.46%	70
2022 Q2	$6.41M	Sell	92,232 -14,670	-14%	-$1.11M	0.48%	70
2022 Q1	$8.86M	Buy	106,902 +8,362	+8%	+$616K	0.5%	67
2021 Q4	$7.4M	Buy	98,540 +12,624	+15%	+$1.27M	0.38%	76
2021 Q3	$9.98M	Buy	85,916 +3,815	+5%	+$577K	0.54%	52
2021 Q2	$18.2M	Buy	82,101 +20,272	+33%	+$3.94M	1%	22
2021 Q1	$8.17M	Buy	61,829 +2,211	+4%	+$350K	0.49%	57
2020 Q4	$10.3M	Buy	59,618 +824	+1%	+$113K	0.6%	49
2020 Q3	$6.54M	Buy	58,794 +32,572	+124%	+$2.6M	0.44%	61
2020 Q2	$1.55M	Hold	26,222	–	–	0.15%	116
2020 Q1	$1.77M	Buy	+26,222	New	+$2.07M	0.2%	108

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Capital International's NVCR Position: Q3 2023 in Review

Capital International sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 82,588 shares — an estimated $3.43M sold.

Capital International first reported a position in NVCR in Q1 2020 and held it in 14 quarters. The position peaked at $18.2M in Q2 2021. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Capital International reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Capital International sold 82,588 NovoCure shares in Q3 2023, an estimated $3.43M.
Capital International first reported a position in NovoCure in Q1 2020 and held it in 14 quarters.
Capital International's NovoCure position peaked at $18.2M in Q2 2021.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Capital International's 13F filing for Q3 2023, filed 13 Nov 2023.